Telix Pharmaceuticals (ASX:TLX) has announced that the last patient has been imaged in a phase one clinical study of the company's investigational prostate cancer imaging product TLX591-CDx.
Telix Japanese prostate cancer imaging study completes enrolment
September 9, 2021 Australian Biotech
Latest Video
New Stories
-
A 'Stronger PBS' makes way for 'We are now in a fight to save the PBS'
June 25, 2026 - - Latest News -
Key report findings - 'Cost of Inaction - Australian voices on equitable access to diabetes technology'
June 25, 2026 - - BioPharma -
New Zealand last among peers for publicly funded modern medicines
June 25, 2026 - - Latest News -
New report highlights the risk of inaction on diabetes technology
June 25, 2026 - - Latest News -
Early real world data shows improvement in treatment resistant depression
June 24, 2026 - - Latest News -
FDA backs AFT’s injectable iron into Phase 3 study as company targets global scale
June 24, 2026 - - Latest News -
Neurizon presents new mechanistic evidence that NUZ-001 restores proteostasis and supports ALS resilience
June 24, 2026 - - Australian Biotech


